8-K: Akari Shareholders Approve Warrants for 44M ADSs

Akari Therapeutics shareholders approved the exercisability of warrants covering over 44 million American Depositary Shares, enabling the issuance of underlying ordinary shares.

Summary

• A Special General Meeting of shareholders was held on March 2, 2026.
• Shareholders approved all five ordinary resolutions submitted for a vote.
• The resolutions pertain to the exercisability of various warrants and the issuance of underlying American Depositary Shares (ADSs) and ordinary shares.
• These warrants were issued in connection with a registered direct offering and concurrent private placement (December 17, 2025, and January 20, 2026), a private placement offering (December 23, 2025), and an exchange of notes (December 17, 2025).
• The approvals cover Series G Warrants, Placement Agent Warrants, Pre-Funded Warrants, and Note Exchange Warrants.
• In total, the approvals enable the exercisability of warrants to purchase up to an aggregate of 44,028,832 American Depositary Shares (ADSs).
• Each ADS represents 2,000 ordinary shares, meaning the approvals cover up to 88,057,664,000 ordinary shares.
• The number of ordinary shares entitled to vote at the meeting was 91,567,009,533.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a largely negative development due to the extremely high potential for dilution, which could nearly double the outstanding share count. While procedural compliance is achieved, the magnitude of potential dilution overshadows this positive.

Positives

• Shareholder approval of all proposals provides clarity and removes uncertainty regarding the exercisability of previously issued warrants.
• Compliance with Nasdaq Listing Rules 5635(c) and 5635(d) ensures continued listing eligibility for the company.
• The ability for warrant holders to exercise could bring additional capital into the company, depending on the exercise prices.

Negatives

• The potential issuance of up to 88,057,664,000 ordinary shares upon warrant exercise represents extremely significant potential dilution for existing shareholders.
• The number of shares underlying warrants is nearly equivalent to the current ordinary shares entitled to vote, indicating a near doubling of the share count if all warrants are exercised.

Risks

• Extremely significant potential dilution of existing shareholders' ownership and earnings per share upon the exercise of the approved warrants, potentially nearly doubling the outstanding share count.
• Substantial downward pressure on the stock price if a large number of ADSs/ordinary shares are issued and subsequently sold in the market.

Future Outlook

The shareholder approvals enable the future exercisability of various warrants, allowing for the potential issuance of a significant number of American Depositary Shares and underlying ordinary shares, which could substantially impact the company's capital structure.

Management Comments

• The report was signed by Kameel Farag, Interim Chief Financial Officer, on behalf of Akari Therapeutics, Plc.

Industry Context

StockSavvy.ai notes that companies, particularly in the biotechnology sector like Akari Therapeutics, frequently utilize warrant issuances in conjunction with capital raises to attract investors, often requiring subsequent shareholder approval to ensure compliance with exchange listing rules. This filing reflects a standard procedural step following previous financing activities.

Corporate Governance

Stakeholder Impact

• Shareholders: Extremely significant potential for dilution of existing shareholdings and earnings per share if warrants are exercised, potentially nearly doubling the outstanding share count.
• Warrant Holders: Warrants are now exercisable, providing them with the option to convert into ADSs/ordinary shares.

Next Steps

• The warrants, whose exercisability was approved, can now be exercised by holders, leading to the potential issuance of American Depositary Shares and ordinary shares.

Key Dates

Recommendation

The approval of warrants that could nearly double the outstanding share count represents an extremely significant dilutive event. This level of potential dilution is highly detrimental to existing shareholder value, likely leading to substantial downward pressure on the stock price and a significant reduction in earnings per share. A 'strong sell' recommendation is warranted given the severe implications for current investors.

Keywords

Akari Therapeutics, AKTX, SEC Filing, 8-K, Shareholder Meeting, Warrants, American Depositary Shares, ADSs, Ordinary Shares, Dilution, Nasdaq Listing Rules, Capital Raise, Private Placement, Registered Direct Offering, Note Exchange